Loading…
Swiss maker of X-ray inspection tubes and RF power/plasma-control systems for semiconductor fabs and industrial imaging.
Swiss maker of X-ray inspection tubes and RF power/plasma-control systems for semiconductor fabs and industrial imaging.
Sells components that stay inside customers' machines, chiefly RF generators and matching networks that power chip-making plasma etch and deposition tools, so orders follow the equipment makers' build plans and a few large customers dominate that unit. The X-ray tubes and Yxlon inspection systems follow a different, industrial cycle.
In one line: A niche Swiss Advanced Energy for RF power.
Moat: narrow (IP / patents, customer qualification, process know-how). Qualified components inside semiconductor tools; switching mid-tool-generation is costly.
Headquarters: Flamatt, Switzerland · Founded: 1948 · Employees: 1,832
Size COMET (COTN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $2.84B, the 80th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 298.00 on 6 Nov 2026.
Performance Over six months the shares fell 9.2%, against +7.9% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 2.8% over the last twelve months (peer median +4.7%); the operating margin is 6.5% (peer median 11.3%).
Valuation It trades at 34.0× forward earnings against a peer median of 26.5× (7th most expensive of 19).
Capital Return on invested capital runs 0.6 points below its cost of capital (7.8% WACC).
Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 470M | CHF 457M | CHF 445M | CHF 397M | CHF 586M |
| Revenue growth | — | +3% | +12% | -32% | — |
| Gross profit | CHF 186M | CHF 174M | CHF 191M | CHF 163M | CHF 262M |
| EBITDA | CHF 52.0M | CHF 39.5M | CHF 51.3M | CHF 37.2M | CHF 114M |
| Net income | CHF 17.8M | CHF 12.2M | CHF 32.8M | CHF 15.4M | CHF 78.1M |
| Free cash flow | -CHF 14.4M | CHF 6.78M | CHF 40.1M | -CHF 2.85M | CHF 42.5M |
| Capital expenditure | CHF 59.8M | CHF 42.6M | CHF 12.8M | CHF 27.0M | CHF 23.2M |
| Total debt | n/a | CHF 91.3M | CHF 97.6M | CHF 95.5M | CHF 97.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| COMET COTN.SW | $2.84B | -9% | -3% | 6% | 34.0× | n/a |
| Advanced Energy Industries AEIS | $7.98B | -45% | +32% | 17% | 11.7× | 17.8% |
| MKS MKSI | $13.0B | -39% | +16% | 17% | 11.5× | 24.0% |
| Varex Imaging VREX | $783M | -10% | +5% | 8% | 20.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | COTN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.1% | +9.0% | 3rd lowest of 21 |
| 6-month return | -9.2% | +7.9% | 6th lowest of 21 |
| Distance from 52-week high | -34.1% | -24.7% | 7th lowest of 21 |
| Revenue growth (TTM) | -2.8% | +4.7% | 2nd lowest of 20 |
| Operating margin | 6.5% | 11.3% | 8th lowest of 20 |
| Forward P/E | 34.0× | 26.5× | 7th most expensive of 19 |
| ROIC minus cost of capital | -0.6 pp | -0.4 pp | 9th lowest of 20 |
| EV / EBITDA | 44.9× | 15.7× | 2nd most expensive of 10 |
| Net debt / EBITDA | 0.4× | 2.6× | 4th least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| COMET COTN.SW | Switzerland | $2.84B | -9% | -3% | 6% | 34.0× | n/a | n/a |
| iRhythm IRTC | United States | $2.97B | -25% | +26% | 1% | 182.6× | n/a | n/a |
| AtriCure ATRC | United States | $2.98B | +123% | +14% | 3% | 220.7× | 55.7% | +20.9% |
| Axogen AXGN | United States | $2.99B | +19% | +24% | -5% | 76.5× | 48.8% | +14.9% |
| TransMedics TMDX | United States | $3.06B | +30% | +26% | 12% | 48.5× | 35.6% | +88.2% |
| Medacta MOVE.SW | Switzerland | $2.61B | -21% | +8% | 15% | 24.3× | n/a | n/a |
| Neogen NEOG | United States | $2.57B | +30% | 0% | 0% | 34.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.56B | -3% | +13% | 26% | 25.9× | 8.3% | +10.4% |
| EBOS EBO.AX | Australia | $2.52B | +1% | +3% | 3% | 15.2× | 4.3% | +6.8% |
| Celcuity CELC | United States | $3.27B | -49% | n/a | n/a | n/a | n/a | n/a |
| Micro-Tech (Nanjing) 688029.SS | China | $2.46B | +3% | +6% | 18% | 29.0× | 12.8% | +19.2% |
| Jafron Biomedical 300529.SZ | China | $2.46B | +8% | +1% | 37% | 25.4× | 6.9% | +0.6% |
| Sumitomo Bakelite 4203.T | Japan | $3.31B | +15% | +15% | 13% | 14.9× | 6.8% | +8.9% |
| Zhende Medical 603301.SS | China | $3.33B | -8% | +8% | 7% | 43.5× | 23.2% | -16.1% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $3.36B | -25% | +5% | 15% | 15.4× | 3.5% | +8.0% |
| Elekta EKTA-B.ST | Sweden | $2.37B | +8% | -7% | 6% | 15.1× | 10.0% | +4.0% |
| Autobio Diagnostics 603658.SS | China | $3.41B | +19% | +3% | 25% | 20.6× | -0.3% | +7.2% |
| MGI Tech 688114.SS | China | $3.42B | +9% | +2% | -7% | n/a | 46.5% | -0.1% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.42B | -12% | -1% | 13% | 26.3× | 9.6% | -4.2% |
| Ambu A/S AMBU-B.CO | Denmark | $3.42B | +40% | +5% | 11% | 28.1× | 12.6% | +11.1% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.51B | +40% | 0% | 8% | 26.8× | 13.7% | +10.8% |